-+ 0.00%
-+ 0.00%
-+ 0.00%

Mira Pharmaceuticals Completes Patient Dosing In Phase 1 Clinical Study Of Ketamir-2; No Serious Adverse Events, Dose-Limiting Toxicities Seen; Plans To File Phase 2a Clinical Trial, Supporting Documents To FDA In H1

Benzinga·03/03/2026 21:33:19
Listen to the news